Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 13/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 10/20 | 0.56 |
| ▸ | TP53BP1 | Q12888 | 2/20 | 0.56 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.56 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | LTA4H | P09960 | 1/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4803745 | 1.00 | L3MBTL3 (0.56) | L3MBTL3L3MBTL1TP53BP1MBTD1SPHK1 | |
| SCHEMBL4808485 | 0.83 | L3MBTL3 (0.60) | L3MBTL3L3MBTL1TP53BP1MBTD1HRH3 | |
| SCHEMBL4808499 | 0.83 | L3MBTL3 (0.60) | L3MBTL3L3MBTL1TP53BP1MBTD1HRH3 | |
| SCHEMBL6799707 | 0.80 | L3MBTL1 (0.55) | L3MBTL1SPHK1HRH3LTA4H | |
| SCHEMBL6799712 | 0.80 | L3MBTL1 (0.55) | L3MBTL1SPHK1HRH3LTA4H | |
| SCHEMBL5537485 | 0.80 | ACHE (0.60) | LTA4H | |
| SCHEMBL5534146 | 0.80 | ACHE (0.60) | LTA4H | |
| SCHEMBL6423692 | 0.80 | ACHE (0.60) | LTA4H | |
| SCHEMBL24008765 | 0.78 | L3MBTL3 (0.60) | L3MBTL3L3MBTL1HRH3MAPT | |
| SCHEMBL4814066 | 0.78 | L3MBTL3 (0.58) | L3MBTL3L3MBTL1TP53BP1MBTD1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7320973-B2 | Dihydrodiaryloxazepine derivative and pharmaceutical composition containing the same | AJINOMOTO CO., INC. (JP) | 2008-01-22 | — | — | US | disclosed |
| US-20040110742-A1 | Dihydrodiaryloxazepine derivative and pharmaceutical composition containing the same | AJINOMOTO CO., INC. (JP) | 2004-06-10 | — | — | US | disclosed |
| EP-1403258-A1 | DIHYDRODIARYLOXAZEPINE DERIVATIVE AND MEDICINAL COMPOSITION CONTAINING THE DERIVATIVE | Ajinomoto Co., Inc. (JP) | 2004-03-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110742-A1 | Dihydrodiaryloxazepine derivative and pharmaceutical composition containing the same | CYP3A4, PPARD, CYP4B1 | L3MBTL3 4874/4885L3MBTL1 4810/4885TP53BP1 4377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.